Sagittarius Life Science (3205) — Cash Flow-to-Debt Ratio
Sagittarius Life Science (3205) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of NT$-21.27 Million could theoretically repay -1% of its total liabilities (NT$26.91 Million) in one year. See Sagittarius Life Science free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sagittarius Life Science Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Sagittarius Life Science across 11 annual periods. Also explore net asset momentum of Sagittarius Life Science to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sagittarius Life Science (2015–2025)
Year-by-year debt coverage analysis for Sagittarius Life Science. For market capitalisation and broader financial context, see market cap of Sagittarius Life Science.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.34x | NT$-36.05 Million | NT$26.91 Million | ▼ -201.4% |
| 2024 | -0.44x | NT$-44.48 Million | NT$100.07 Million | ▲ +11.7% |
| 2023 | -0.50x | NT$-69.37 Million | NT$137.82 Million | ▼ -17.7% |
| 2022 | -0.43x | NT$-52.89 Million | NT$123.70 Million | ▼ -111.0% |
| 2021 | -0.20x | NT$-29.18 Million | NT$144.03 Million | ▲ +50.4% |
| 2020 | -0.41x | NT$-62.24 Million | NT$152.36 Million | ▲ +46.4% |
| 2019 | -0.76x | NT$-104.50 Million | NT$137.09 Million | ▼ -27.0% |
| 2018 | -0.60x | NT$-57.86 Million | NT$96.38 Million | ▼ -150.2% |
| 2017 | -0.24x | NT$-23.31 Million | NT$97.16 Million | ▼ -113.4% |
| 2016 | 1.80x | NT$360.37 Million | NT$200.51 Million | ▲ +215.0% |
| 2015 | 0.57x | NT$237.94 Million | NT$416.95 Million | — |